Bone News and Research RSS Feed - Bone News and Research

Jazz Pharmaceuticals to present defibrotide results for hepatic VOD at BMT Tandem meetings

Jazz Pharmaceuticals to present defibrotide results for hepatic VOD at BMT Tandem meetings

Jazz Pharmaceuticals plc announced today that researchers will present data on the use of defibrotide, an investigational medicine being studied in the United States (U.S.) for the treatment of hepatic veno-occlusive disease (VOD), a rare, potentially life-threatening, early complication in patients undergoing hematopoietic stem-cell transplantation (HSCT) therapy. [More]
Cochlear announces winners of Graeme Clark and Anders Tjellstrom Scholarships

Cochlear announces winners of Graeme Clark and Anders Tjellstrom Scholarships

Cochlear Limited (ASX: COH), the global leader in implantable hearing solutions, announced today the winners of the 13th annual Graeme Clark and the fourth annual Anders Tjellstrom Scholarships. [More]
Stem cell transplants more effective than mitoxantrone drug for people with severe multiple sclerosis

Stem cell transplants more effective than mitoxantrone drug for people with severe multiple sclerosis

Stem cell transplants may be more effective than the drug mitoxantrone for people with severe cases of multiple sclerosis (MS), according to a new study published in the February 11, 2015, online issue of Neurology, the medical journal of the American Academy of Neurology. [More]
Researchers develop new method for preventing destructive activity of osteoclasts

Researchers develop new method for preventing destructive activity of osteoclasts

Most existing treatments for pathological bone loss inhibit osteoclasts (bone-destroying cells) to limit bone degradation. However, by doing this, they also prevent bone formation since it is stimulated by the presence of these very same osteoclast cells. Researchers from the CNRS, Inserm and the Université de Montpellier and Université Jean Monnet - Saint-étienne have developed a new approach for preventing the destructive activity of osteoclasts without affecting their viability. [More]
Longer donor leukocyte telomere length linked to improved survival following HCT

Longer donor leukocyte telomere length linked to improved survival following HCT

Among patients with severe aplastic anemia who received stem cell transplant from an unrelated donor, longer leukocyte (white blood cells) telomere length (a structure at the end of a chromosome) was associated with increased overall survival at 5 years, according to a study in the February 10 issue of JAMA. [More]
Single-use TorqueSafe instruments use Bayer's Makrolon polycarbonate resin

Single-use TorqueSafe instruments use Bayer's Makrolon polycarbonate resin

For many years, torque-applying instruments have been among the surgical instruments typically used during orthopedic surgeries. [More]
Griffith study shows resistance training improves bone, muscle strength in post-menopausal women

Griffith study shows resistance training improves bone, muscle strength in post-menopausal women

Big improvements in strength with no injuries have been the hallmarks of success with a Griffith University study looking at the physical function of post-menopausal women. [More]
Researchers generate new reporter system to study bone regeneration potential of embryonic stem cells

Researchers generate new reporter system to study bone regeneration potential of embryonic stem cells

A new reporter system used to study the bone regeneration potential of human embryonic stem cells has been generated in research led by the University of Minnesota. The new reporter system is the first of its kind for human pluripotent stem cells and is important for identifying certain agents and pathways that mediate early stages of human bone development. [More]
Research findings could lead to new standard of care for soft tissue sarcomas

Research findings could lead to new standard of care for soft tissue sarcomas

Using advanced imaging technology to more precisely target radiation beams to treat soft tissue cancers (sarcomas) in the extremities significantly reduces long term side effects without effecting survival rates, according to research results published online today in the Journal of Clinical Oncology. [More]
DePuy Synthes announces acquisition of Olive Medical

DePuy Synthes announces acquisition of Olive Medical

Today DePuy Synthes Companies announced that it has acquired Olive Medical Corporation, a Utah-based privately held provider of high definition (HD) visualization systems for minimally invasive surgery (MIS). Financial terms of the transaction were not disclosed. [More]
Bayer materials withstand demanding conditions and meet requirements for innovative medical devices MD&M West

Bayer materials withstand demanding conditions and meet requirements for innovative medical devices MD&M West

Increasingly, innovative medical applications place further importance on the success of the materials they use. When patients’ health, mobility and comfort are involved, reliability and durability are crucial. Bayer MaterialScience LLC steps up to the challenge offering original equipment manufacturers (OEMs) a wide range of material solutions for their medical application needs. [More]
Bayer offers wide range of material solutions for OEMs' medical application needs

Bayer offers wide range of material solutions for OEMs' medical application needs

Increasingly, innovative medical applications place further importance on the success of the materials they use. When patients' health, mobility and comfort are involved, reliability and durability are crucial. Bayer MaterialScience LLC steps up to the challenge offering original equipment manufacturers (OEMs) a wide range of material solutions for their medical application needs. [More]
Japanese researchers explore use of bone marrow transplants to treat hypophosphatasia

Japanese researchers explore use of bone marrow transplants to treat hypophosphatasia

Recent research carried out by a team of researchers in Japan has investigated the use of bone marrow transplants (BMTs) to treat hypophosphatasia (HPP). In this study, the researchers carried out BMT for two infants with HPP in combination with allogenic (other-donated) mesenchymal stem cell transplants (MSCTs). The allogenic MSC donors were a parent of the infant. [More]
New stent for treating cardiovascular disease successfully implanted in patients

New stent for treating cardiovascular disease successfully implanted in patients

A new stent for treating cardiovascular disease that incorporates a polymer invented at Rutgers, The State University of New Jersey, has been implanted in patients for the first time. [More]
Duke University researchers devise new method to activate genes with light

Duke University researchers devise new method to activate genes with light

Duke University researchers have devised a method to activate genes in any specific location or pattern in a lab dish with the flip of a light switch by crossing a bacterium's viral defense system with a flower's response to sunlight. [More]

Cohera Medical gets FDA approval to distribute TissuGlu Surgical Adhesive in US

Cohera Medical, Inc.®, a leading innovator and developer of surgical adhesives and sealants, announced today that the U.S. Food and Drug Administration (FDA) has approved its TissuGlu® Surgical Adhesive. [More]
DNA strands predict life expectancy

DNA strands predict life expectancy

BYU biologist Jonathan Alder has a startling secret he doesn't freely share: he knows when most of us are going to die. [More]
CLL aggressiveness linked to genetic variability

CLL aggressiveness linked to genetic variability

The genetic variability of a tumour could be a predictor for its aggressiveness: the greater the variability in gene expression, the more aggressive the tumour is likely to be. This is the hypothesis that the CNIO Structural Biology and Biocomputing Programme, led by Alfonso Valencia, is testing, after their findings on chronic lymphocytic leukaemia (CLL), now published in the journal Genome Medicine. [More]
Breakthrough therapies for blood cancers may provide reasonable value for money spent

Breakthrough therapies for blood cancers may provide reasonable value for money spent

Amid the growing debate about the high price of powerful new drugs in the United States, a recent analysis suggests that breakthrough therapies for blood cancers may, in many cases and with some important caveats, provide reasonable value for money spent. [More]
Breakthrough blood cancer therapies may provide reasonable value for money spent

Breakthrough blood cancer therapies may provide reasonable value for money spent

Amid the growing debate about the high price of powerful new drugs in the United States, a recent analysis suggests that breakthrough therapies for blood cancers may, in many cases and with some important caveats, provide reasonable value for money spent. [More]